BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

Valneva gets $130M up front in Lyme disease vaccine deal  Pfizer Inc. (NYSE:PFE) will collaborate with Valneva SE (Euronext:VLA) to develop VLA15, the biotech’s vaccine candidate for Lyme disease. In a deal announced Thursday, Valneva...
BC Week In Review | Apr 13, 2018
Clinical News

Valneva reports Phase I data for Lyme disease vaccine candidate

Valneva SE (Euronext Paris:VLA; VSE:VLA) reported interim data from a Phase I trial in 179 healthy volunteers ages 18-40 showing that Lyme disease candidate VLA15 (VLA15-101) met the primary endpoint by achieving a "favorable" safety...
BC Week In Review | Dec 13, 2016
Clinical News

VLA15-101: Ph I started

Valneva began a single-blind, dose-escalation, international Phase I trial to evaluate VLA15-101 in about 180 healthy volunteers. Valneva SE (Euronext:VLA; VSE:VLA), Lyon, France  Product: VLA15-101  Business: Infectious  Molecular target: Borrelia outer surface protein A (ospA)...
BC Innovations | Jan 8, 2015
Distillery Therapeutics

Therapeutics: Borrelia outer surface protein A (ospA)

Infectious disease INDICATION: Lyme disease Mouse studies suggest a stable hexavalent recombinant ospA vaccine could protect against most Borrelia species that cause Lyme disease. The vaccine consists of three heterodimer fusion proteins constructed from the...
BC Innovations | Jan 8, 2015
Translation in Brief

Uptick for Lyme vaccine

Commercial interest in Lyme disease has all but ground to a halt since the withdrawal of the first vaccine, Lymerix, more than a decade ago, despite a tenfold increase in the U.S. incidence of the...
BC Week In Review | May 13, 2013
Clinical News

Lyme disease vaccine: Phase I/II data

A double-blind, German and Austrian Phase I/II trial in 300 healthy volunteers aged 18-70 years showed that Baxter's Lyme disease vaccine induced "substantial" antibody titers against all targeted species of Borrelia, the causative agent of...
BC Week In Review | Jul 10, 2000
Clinical News

Lyme disease laboratory diagnostic regulatory update

The Mayo Foundation received U.S. Patent No. 6,045,804 covering a Lyme disease diagnostic that uses OspA deficient antigens from mutant Borrelia burgdorferi. The test, which is exclusively licensed to Imugen, is used to detect infection...
BC Week In Review | Feb 22, 2000
Clinical News

ImuLyme: Discontinued Development

Aventis Pasteur Inc., Swiftwater, Penn.   Product: ImuLyme   Business: Infectious diseases   Therapeutic category: Immune stimulation, Bacterial infection   Target: Immune cells   Description: Recombinant outer-surface protein A (OspA) of Borrelia burgdorferi   Indication:...
BC Week In Review | Jul 12, 1999
Clinical News

MedImmune Inc. preclinical data

In mice, a combination vaccine developed by MEDI and partner Pasteur Merieux Connaught prevented infection at all challenge doses of Borrelia burgdorferi bacteria. Low doses of the combination vaccine were more effective than higher doses...
BC Week In Review | Jan 4, 1999
Clinical News

SmithKline Beecham Biologicals regulatory update

The FDA granted marketing approval for SmithKline's Lymerix vaccine containing recombinant outer-surface lipoprotein A (OspA) of Borrelia burgdorferi to prevent Lyme disease. SmithKline Beecham Biologicals, Rixensart, Belgium   Business: Infectious diseases  ...
Items per page:
1 - 10 of 18